Medical/Pharmaceuticals
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18
BEIJING and BRIDGEWATER, N.J., Dec. 7, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the...
RaySearch receives large RayStation order in China for carbon ion treatment planning
RaySearch Laboratories AB (publ) announces a large order for the treatment planning system RayStation®* by Lanzhou Ion Therapy Co, LTD, a Chinese manufacturer of accelerator systems for carbon ion therapy STOCKHOLM, Dec. 7, 2021 /PRNewswire/ -- Carbon ion therapy is a highly advanced radiation t...
Moscow ranked first among European cities in the ranking of innovations against COVID-19
Moscow ranks third in the world, behind New York and San Francisco MOSCOW, Dec. 7, 2021 /PRNewswire/ -- Moscow is recognized as the first European city in the ranking of innovations, that are used for the formation of resilience to the coronavirus. It is ahead ofLondon and Barcelona. The Russian...
Effort to reduce burden of disease in Australia shines spotlight on natural medicine to support liver health
SYDNEY, Dec. 7, 2021 /PRNewswire/ -- The prevalence of liver health issues is emerging as a serious cost and health burden forAustralia with the spotlight on evidence-based natural ingredients that might help support liver health and possibly assist in reducing the burden of the disease[i]. A ne...
Broncus enter into strategic partnership with New Frontier Health Corporation /United Family Healthcare
HANGZHOU, China, Dec. 6, 2021 /PRNewswire/ -- Broncus Holding Corporation (2216.HK) ("Broncus"), the leader of minimally invasive diagnostic and therapeutic technology for solutions to different lung diseases inChina, today announced that it has entered into a strategic cooperation framework agre...
RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations
Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other variants of conce...
Innoforce Completes Second Tranche of Series A Financing
HANGZHOU, China, Dec. 6, 2021 /PRNewswire/ -- Innoforce ("INF"), a biopharmaceutical manufacturing & development company, announced today the completion of a1 billion CNY ($156.6M) Series A financing, with the closing of an additional375M CNY ($58.7M) following the first tranche of 625M CNY ($96M...
Donisi Health Named 2021's "Future Unicorn" by E&T Magazine
MedTech Startup Focused on Home Monitoring for Patients with Congestive Heart Failure and Other Chronic Diseases Receives the "Future Unicorn" Innovation Award from E&T TEL AVIV, Israel, Dec. 6, 2021 /PRNewswire/ -- E&T Magazine, the official publication of the Institution of Engineering and Tec...
Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies
HOUSTON and SINGAPORE, Dec. 6, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, and Cancer Research UK, the world's leading cancer charity, today annou...
IMPACT 2021 R&D Day: Synthetic Lethality Provides a New Platform for Targeted Cancer Therapy
SHANGHAI, Dec. 6, 2021 /PRNewswire/ -- The 2nd R&D Day event of IMPACT Therapeutics (IMPACT) successfully took place inShanghai on December 3rd (GMT+8). With the theme of "Synthetic Lethality: A New Platform for Targeted Therapy", the event attracted nearly 300 guests offline and online. The gues...
Odyssey Announces Agreement to Combine with BenevolentAI
* BenevolentAI is a leading, clinical-stage AI drug discovery company that combines advanced AI and machine learning with cutting edge science to discover and develop novel and more effective medicines * Combination of BenevolentAI with Odyssey, a €300m Euronext Amsterdam-listed special purpo...
Odyssey Announces Agreement to Combine with BenevolentAI
LONDON and AMSTERDAM, Dec. 6, 2021 /PRNewswire/ -- Odyssey Acquisition S.A. ("Odyssey"), a Euronext Amsterdam-listed special-purpose acquisition company, and BenevolentAI, a leading clinical-stage AI drug discovery company, today announced that they have entered into a definitive agreement for a ...
Brii Biosciences Included in Hong Kong Stock Connect
DURHAM, N.C. and BEIJING, Dec. 6, 2021 /PRNewswire/ -- Brii Biosciences
OMRON and Doctor Anywhere announce collaboration for digitally enhanced remote hypertension and health management program
* Initiative to strengthen OMRON's vision of 'Going For Zero' (heart attacks and strokes). SINGAPORE, Dec. 6, 2021 /PRNewswire/ -- OMRON Healthcare, the global leader in the field of clinically proven and innovative medical equipment for health monitoring and therapy has announced a strategic ...
Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China
BEIJING and SHANGHAI and BOSTON, Dec. 5, 2021 /PRNewswire/ -- Jacobio Pharma ( 1167.HK) has received the Investigational New Drug (the "IND") approval of the combination therapy of KRAS G12C inhibitor JAB-21822 and Cetuximab injection from the Center for Drug Evaluation ofChina (the "CDE") on Dec...
Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma
SYDNEY, Dec. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The res...
Henlius' 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by National Medical Products Administration
SHANGHAI, Dec. 4, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that bevacizumab biosimilar Hanbeitai, developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA). It is indicated for the treatment of meta...
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients have been dosed in the U.S. p...
OrigiMed announced its strategic partnership with Janssen to develop clinical innovative solutions driven by data science
SHANGHAI, Dec. 3, 2021 /PRNewswire/ -- OrigiMed Co., Ltd. ("OrigiMed") announced that the company has signed a memorandum of understanding (MoU) on strategic collaboration with Janssen (China) Research and Development Center of Johnson & Johnson (China) Investment Co., Ltd. ("Janssen").Zili Li, M...
Biotheus' Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies
ZHUHAI, China, Dec. 3, 2021 /PRNewswire/ -- Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA (United States Food and Drug Administration) for conducting clinical phase II studies as part of an international m...
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 291 media titles]
2024-04-22 16:00Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 290 media titles]
2024-04-22 06:00With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 287 media titles]
2024-04-18 21:26China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 286 media titles]
2024-04-19 13:25Animated Life in Yunnan
[Picked up by 281 media titles]
2024-04-18 14:00